Enasidenib mesylate (1650550-25-6)
Enasidenib is a first-in-class oral selective inhibitor of mutant IDH2 enzymes (isocitrate dehydrogenase 2), for the treatment of adults with relapsed or refractory IDH2-mutated acute myeloid leukemia. Product Name: Enasidenib mesylate CAS No.: 1650550-25-6 Assay: 98% Specification: CP, EP, In-house...
FARMASINO Enasidenib Mesylate
,FARMASINO Enasidenib manufacturer
,FARMASINO Enasidenib API
Enasidenib is a first-in-class oral selective inhibitor of mutant IDH2 enzymes (isocitrate dehydrogenase 2), for the treatment of adults with relapsed or refractory IDH2-mutated acute myeloid leukemia.
| Product Name: | Enasidenib mesylate |
| CAS No.: | 1650550-25-6 |
| Assay: | 98% |
| Specification: | CP, EP, In-house, as required |
| Molecular Formula: |
C20H21F6N7O4S |
| Molecular Weight: |
569.48 |
| Shelf Life: | 2 Years |
| Package: | 25kg/drum |
![]()
![]()
![]()